European Society for Medical Oncology

Basilea reports data from poster presentations at ESMO Virtual Congress 2020

Tuesday, September 22, 2020 - 6:15am

Basilea Pharmaceutica Ltd. (SIX: BSLN) today reports on several e-posters with new preclinical and clinical data on its fibroblast growth factor receptor (FGFR) inhibitor derazantinib and its tumor checkpoint controller, lisavanbulin, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which took place from 19-21 September, 2020.

Key Points: 
  • Basilea Pharmaceutica Ltd. (SIX: BSLN) today reports on several e-posters with new preclinical and clinical data on its fibroblast growth factor receptor (FGFR) inhibitor derazantinib and its tumor checkpoint controller, lisavanbulin, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which took place from 19-21 September, 2020.
  • In addition, gastric and lung cancer models showed the strongest correlation of FGFR1-3 expression versus the anticancer activity of derazantinib.
  • The results support the planned clinical investigation of derazantinib in gastric cancer as its next indication.
  • Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN).

NuCana Presents Three Posters at the ESMO Virtual Congress 2020

Monday, September 21, 2020 - 9:02pm

EDINBURGH, United Kingdom, Sept. 21, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), announced data from the ongoing NUC-3373 and NUC-7738 clinical programs, as well as a review of the ongoing Acelarin Phase III study, at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress.

Key Points: 
  • EDINBURGH, United Kingdom, Sept. 21, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), announced data from the ongoing NUC-3373 and NUC-7738 clinical programs, as well as a review of the ongoing Acelarin Phase III study, at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress.
  • NuCana believes these data support the potential of NUC-3373 to improve progression-free survival in patients who had relapsed or were refractory to prior 5-FU containing regimens.
  • NuCana also believes these data show NUC-3373s potential to offer enhanced efficacy, an improved safety profile and a more convenient dosing regimen as compared to 5-FU.
  • Additionally, interim data from two case studies showed the significant reductions in tumor volume were maintained over time in these patients.

Provectus Biopharmaceuticals Highlights Stage IV M1c Patient Outcome from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Naïve Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020

Monday, September 21, 2020 - 5:45pm

Two-year landmark survival, response, and safety data from this CB-nave cohort were previously presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, held online from September 19-21, 2020.

Key Points: 
  • Two-year landmark survival, response, and safety data from this CB-nave cohort were previously presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, held online from September 19-21, 2020.
  • Provectus' RBD and cGMP RBD manufacturing process are protected by composition of matter and manufacturing patents as well as trade secrets.
  • Patients with at least one injectable lesion and who were candidates for KEYTRUDA were eligible.
  • Information about the Companys clinical trials can be found at the National Institutes of Health (NIH) registry, www.clinicaltrials.gov .

Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020

Monday, September 21, 2020 - 3:20pm

Genmab A/S (Nasdaq: GMAB) and Seattle Genetics, Inc. (Nasdaq: SGEN) today presented data from the innovaTV 204 pivotal phase 2, single-arm clinical trial evaluating tisotumab vedotin as monotherapy in patients with previously treated recurrent and/or metastatic cervical cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Key Points: 
  • Genmab A/S (Nasdaq: GMAB) and Seattle Genetics, Inc. (Nasdaq: SGEN) today presented data from the innovaTV 204 pivotal phase 2, single-arm clinical trial evaluating tisotumab vedotin as monotherapy in patients with previously treated recurrent and/or metastatic cervical cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
  • Tisotumab vedotin has demonstrated meaningful clinical activity in patients with recurrent and/or metastatic cervical cancer for whom there is a high unmet need for new therapies, said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics.
  • Data presented at ESMO include the primary endpoint of confirmed ORR as assessed by independent central review in 101 patients treated with tisotumab vedotin in the trial.
  • For more information about the phase 2 innovaTV 204 clinical trial and other clinical trials with tisotumab vedotin, please visit www.clinicaltrials.gov.

Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020

Monday, September 21, 2020 - 3:20pm

Seattle Genetics, Inc. (Nasdaq:SGEN) and Genmab A/S (Nasdaq: GMAB) today presented data from the innovaTV 204 pivotal phase 2, single-arm clinical trial evaluating tisotumab vedotin as monotherapy in patients with previously treated recurrent and/or metastatic cervical cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Key Points: 
  • Seattle Genetics, Inc. (Nasdaq:SGEN) and Genmab A/S (Nasdaq: GMAB) today presented data from the innovaTV 204 pivotal phase 2, single-arm clinical trial evaluating tisotumab vedotin as monotherapy in patients with previously treated recurrent and/or metastatic cervical cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
  • We are encouraged by the innovaTV 204 trial results, which suggests that tisotumab vedotin as a monotherapy could potentially become an important option for women with metastatic and or recurrent cervical cancer, said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
  • Data presented at ESMO include the primary endpoint of confirmed ORR as assessed by independent central review in 101 patients treated with tisotumab vedotin in the trial.
  • For more information about the phase 2 innovaTV 204 clinical trial and other clinical trials with tisotumab vedotin, please visit www.clinicaltrials.gov.

Sensei Biotherapeutics Reports Early Data from Phase 1/2 Clinical Trial of SNS-301 in Combination with Pembrolizumab in Advanced Head and Neck Cancer Patients at ESMO 2020

Friday, September 18, 2020 - 1:01pm

The data were presented in a poster discussion session at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Key Points: 
  • The data were presented in a poster discussion session at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
  • Patients with SCCHN often present with immune desert or excluded tumors and only 13-16% of the patients respond to anti PD-1/PDL-1 therapy.
  • This initial data from 9 patients provides us with the rationale to continue exploring its safety and efficacy in 1st and 2nd line SCCHN patients.
  • An additional study in neoadjuvant SCCHN patients is planned to begin early next year in combination with Imfimzi (durvalumab).

Alkermes Presents New Clinical Data on ALKS 4230 in Mini Oral Presentation at 2020 European Society for Medical Oncology (ESMO) Virtual Congress

Friday, September 18, 2020 - 11:30am

Data from the ongoing ARTISTRY-1 study showed encouraging single-agent activity of ALKS 4230 in melanoma and durable responses in multiple tumor types in combination with pembrolizumab.

Key Points: 
  • Data from the ongoing ARTISTRY-1 study showed encouraging single-agent activity of ALKS 4230 in melanoma and durable responses in multiple tumor types in combination with pembrolizumab.
  • These data are being presented in a mini oral presentation at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress, held Sept. 18-21.
  • As of July 27, 2020, the patient had experienced a total tumor shrinkage of 39% and was continuing monotherapy treatment.
  • Since the July 24, 2020 data cut, one additional melanoma patient achieved a PR, awaiting a confirmatory scan.

Alkermes Presents New Clinical Data on ALKS 4230 in Mini Oral Presentation at 2020 European Society for Medical Oncology (ESMO) Virtual Congress

Friday, September 18, 2020 - 11:30am

Data from the ongoing ARTISTRY-1 study showed encouraging single-agent activity of ALKS 4230 in melanoma and durable responses in multiple tumor types in combination with pembrolizumab.

Key Points: 
  • Data from the ongoing ARTISTRY-1 study showed encouraging single-agent activity of ALKS 4230 in melanoma and durable responses in multiple tumor types in combination with pembrolizumab.
  • These data are being presented in a mini oral presentation at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress, held Sept. 18-21.
  • As of July 27, 2020, the patient had experienced a total tumor shrinkage of 39% and was continuing monotherapy treatment.
  • Since the July 24, 2020 data cut, one additional melanoma patient achieved a PR, awaiting a confirmatory scan.

Genetron Health to Highlight Data from 18 Studies at ESMO 2020

Friday, September 18, 2020 - 11:00am

The abstracts include 15 studies on translational medicine covering various cancer types and three studies on bioinformatics development.

Key Points: 
  • The abstracts include 15 studies on translational medicine covering various cancer types and three studies on bioinformatics development.
  • Data that will be highlighted at the ESMO Virtual Congress were generated in collaboration with more than 10 notable cancer centers and clinical hospitals in China.
  • These studies aim at gathering specific data for the Chinese population in order to design precision oncology therapies for the domestic market.
  • We are pleased to showcase our data from 18 research studies at the upcoming ESMO Virtual Congress.

New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline

Thursday, September 17, 2020 - 8:05am

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the data being presented as e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Key Points: 
  • Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the data being presented as e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
  • The ARIEL3 data presented in an e-poster reinforce the overall safety profile of Rubraca as a maintenance treatment in patients with recurrent ovarian cancer.
  • Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets.
  • Clovis Oncology is headquartered in Boulder, Colorado, with additional office locations in the U.S. and Europe.